Omar Rosales

Mr. Omar Rosales

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
WCWilson L. da Costa
Wilson L. da Costa
DGDanielle Guffey
Danielle Guffey
AOAbiodun Oluyomi
Abiodun Oluyomi
RBRaka Bandyo
Raka Bandyo
OROmar Rosales
Omar Rosales
ALAng Li
Ang Li

9 December 2022 in AJPM Focus
Verified
Journal Article
Open access
ISItunu Sokale
Itunu Sokale
OROmar Rosales
Omar Rosales
JMJane R. Montealegre
Jane R. Montealegre
AOAbiodun O Oluyomi
Abiodun O Oluyomi
ATAaron P. Thrift
Aaron P. Thrift
Mortality rates from colorectal cancer have declined over the past decades owing to population-based life-saving screening interventions. However, screening inequalities continue among racial and ethnic minorities despite having a higher disease burden. In this study, we assessed the patterns of up-to-date colorectal cancer screening rates among racial/ethnic groups across the U.S. Census Bureau Divisions. This population-based cross-sectional study used weighted data from 4 cycles of the Behavioral Risk Factors Surveillance System (2014, 2016, 2018, and 2020) of adults aged 50‒75 years without a previous diagnosis of colorectal cancer. The primary outcome was guideline-recommended up-to-date colorectal cancer screening. We used logistic regression models to examine temporal trends in up-to-date colorectal cancer screening from 2014 to 2020. In addition, we conducted detailed descriptive statistics of up-to-date screening rates, comparing trends in 2020 with those in 2014 overall by race/ethnicity and U.S. census divisions. The overall proportion of individuals with up-to-date colorectal cancer screening increased from 66.5% in 2014 to 72.5% in 2020 (p<0.001). For racial/ethnic subgroups, from 2014 to 2020, screening rates increased significantly among non-Hispanic Whites (68.5%‒74.5%, p<0.001), non-Hispanic Blacks (68.0%‒74.6%, p<0.001), and Hispanics (51.5%‒62.8%, p<0.001). However, increases were not observed in all U.S. Census Bureau Divisions. Although colorectal cancer screening rates improved over time, they fall short of the 80% target. Substantial racial/ethnic and geographic disparities remain. Future studies investigating the factors influencing these disparities are needed.

1 December 2020 in Epilepsy & Behavior
Verified
Journal Article
Closed access
RSRoss Shegog
Ross Shegog
CBCharles Begley
Charles Begley
JCJenny Chong
Jenny Chong
RSRefugio Sepulveda
Refugio Sepulveda
RARobert Addy
Robert Addy
DLDavid Labiner
David Labiner

1 December 2021 in Epilepsy & Behavior
Verified
Journal Article
Closed access
SOSusanna S. O'KUla
Susanna S. O'KUla
FBFarren B. S. Briggs
Farren B. S. Briggs
BBBrittany Brownrigg
Brittany Brownrigg
KSKaylee Sarna
Kaylee Sarna
OROmar Rosales
Omar Rosales
TSTanya M. Spruill
Tanya M. Spruill

25 June 2024 in Cancer
Verified
Journal Article
Closed access
THThanh T. Hoang
Thanh T. Hoang
RRRutu A. Rathod
Rutu A. Rathod
OROmar Rosales
Omar Rosales
MCMaria I. Castellanos
Maria I. Castellanos
JSJeremy M. Schraw
Jeremy M. Schraw
EBElyse N. Burgess
Elyse N. Burgess

24 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ISItunu Sokale
Itunu Sokale
OROmar Rosales
Omar Rosales
ATAaron P. Thrift
Aaron P. Thrift
HEHashem El-Serag
Hashem El-Serag
EBElyse N. Burgess
Elyse N. Burgess
AOAbiodun O Oluyomi
Abiodun O Oluyomi
Background/Objectives: Hepatocellular carcinoma (HCC) is a leading cause of cancer diagnoses and deaths in the United States. This study serves as an update on secular trends in national HCC incidence rates while exploring potential geographic and racial/ethnic differences across all nine US census divisions. Methods: We analyzed HCC incidence data reported to the United States Cancer Statistics (USCS) database from 2001 to 2021 (excluding 2020 data, based on the Centers for Disease Control and Prevention’s cautionary recommendations for COVID-19 pandemic data usage for trend analysis). We performed trend analyses of age-adjusted incidence rates in the US overall, by census divisions, and then stratified by race/ethnicity, using the National Cancer Institute’s Joinpoint Regression Program. Results: Between 2001 and 2021, HCC incidence rates increased nationally, with an average annual percentage change (AAPC) of 2.51 (95% confidence interval (CI): 2.32–2.72); however, the rate decreased (annual percentage change (APC) −3.33 (95% CI: −4.78–−1.96) in recent years from 2018 to 2021. Division 1 had the greatest decrease (APC −6.46 (95% CI: −9.62–−3.96) from 2017 to 2021, while rates leveled in Division 6 (East South Central) and Division 7 (West South Central). HCC trends decreased substantially for non-Hispanic Black and Non-Hispanic Asian and Pacific Islander groups in almost all divisions in recent years, but trends were stable, decreased, or increased for other racial/ethnic populations. Conclusions: Despite declining national HCC incidence rates, these trends were not uniform across racial/ethnic groups or US census divisions. Race-specific interventions are needed to reduce disparities in HCC incidence in all US census divisions.